Beyond viral vaccines, attenuated bacterial infections have garnered attention for their potential therapeutic applications. Attenuation in bacteria involves weakening their virulence while maintaining essential features for triggering an immune response. This approach has been explored in the development of live attenuated bacterial vaccines against pathogens like Mycobacterium tuberculosis. Attenuated strains can serve as carriers for vaccine antigens, delivering them to the immune system while eliciting protective immune responses. Attenuated bacteria also hold promise in cancer therapy. Engineered bacteria, such as Salmonella or Escherichia coli, can be used as delivery vehicles for therapeutic agents, including anticancer drugs or immunomodulators. These bacteria preferentially accumulate in tumors due to their unique microenvironment, providing a targeted and localized treatment approach. Researchers are actively investigating the safety, efficacy, and potential side effects of such attenuated bacterial therapies. The development and application of attenuated bacterial strains require a comprehensive understanding of bacterial pathogenesis, host responses, and the intricacies of the targeted disease. Balancing attenuation to ensure safety while preserving immunogenicity remains a critical challenge in these endeavors. Ongoing research aims to optimize these approaches for a range of therapeutic purposes, opening new avenues in the fields of infectious diseases and cancer therapeutics.